Skip to main content
GIPResearch.com · Patent and Technology Research

INNOVATE PHARMACEUTICALS LIMITED GRANTED PATENT FOR SALICYLATE COMPOUND COMPOSITION.

Innovate Pharmaceuticals Limited is a research-based development stage pharmaceutical company that discovers and develops innovative medicines.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for INNOVATE PHARMACEUTICALS LIMITED GRANTED PATENT FOR SALICYLATE COMPOUND COMPOSITION.
Research and original publication material

INNOVATE PHARMACEUTICALS LIMITED GRANTED PATENT FOR SALICYLATE COMPOUND COMPOSITION. — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Innovate Pharmaceuticals Limited is a research-based development stage pharmaceutical company that discovers and develops innovative medicines. They influence Innovate's exclusive supra-molecular chemistry policy in the detection and design of novel cures for areas of unmet requirement. Innovate Pharmaceuticals filed a patent application numbered 201717026076 that is titled SALICYLATE COMPOUND COMPOSITION. The patent has been filed in the field of Pharmaceuticals. This Patent Application has been granted as Patent Number 351106. This invention covers a liquid composition comprising a salicylate compound, glycerin triacetate, and accharin, wherein the salicylate compound is selected from the group consisting of aspirin, triflusal, and salsalate, wherein the composition comprises 0.5 to 7 wt% salicylate compound and 90 to 99 wt% glycerin triacetate. During the patent examination, the Patent Examiner raised objections stating that the composition comprises salicylate compound, glycerol derivative, saccharin, and flavoring agent of the alleged invention is a mere new form of known composition in the view of the prior art. There is no therapeutic efficacy is given of the composition in the claims. Therefore, the invention fell under Section 3(d) of the Patents Act and not patentable. As a response, the Applicant submitted that the learned Controller acknowledged the novelty of a previous claim which specified that the saccharin compound is saccharin. The independent claims all specify that the saccharin compound is saccharin. For at least this reason, all claims are novel. It cannot be considered as a new form of a known substance. Hence amended set of the claims did not fall under the purview of Section 3(d). Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to INNOVATE PHARMACEUTICALS LIMITED GRANTED PATENT FOR SALICYLATE

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2020-11-23. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights